30-day average of 14 articles · scale −100 to +100
Across 14 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Boston Scientific news is Neutral (+1)
on a scale from −100 to +100.
That is up 9 points from the previous 30 days (-8).
💊 WATCHMAN FLX Pro trials show noninferiority with reduced bleeding risks.
📉 Global recalls for Neuromodulation discs and microcatheters create operational risks.
Slightly Bullish +15
Boston Scientific stock faces recall scrutiny across device lines
AI-generated analysis
Key insights
📉 Boston Scientific faces operational risks from multiple Class II recalls involving Neuromodulation therapy discs and Direxion Torqueable Microcatheters distributed globally.
⚠️ Quality control issues could lead to rework costs, regulatory scrutiny, and disruption in interventional and neuromodulation product lines.
🔍 Recalls add pressure to the WATCHMAN and electrophysiology franchises which are already facing volume trends challenges.
💊 Recent trial results for the WATCHMAN FLX Pro device demonstrated noninferiority with reduced bleeding risks compared to dual antiplatelet therapy.
📈 Analysts project US$23.0 billion revenue and US$4.0 billion earnings by 2029 based on a 2.9% annual growth rate.
🚀 Optimistic estimates suggest potential for US$24.4 billion revenue and US$4.4 billion earnings by 2029 if execution targets are met.
🤝 The company's future performance depends on offsetting weaker franchises with its cardiovascular and MedSurg portfolios.
💰 Strategic growth relies on successful restructuring savings and the integration of the planned Penumbra acquisition.
📈 Bullish signals
💊Recent clinical trial results for the WATCHMAN FLX Pro device showed noninferiority for aspirin alone or reduced-dose NOAC regimens versus dual antiplatelet therapy at six months.
💊The findings from the WATCHMAN FLX Pro trials indicate similar ischemic stroke rates and less bleeding, which could support the franchise if left atrial appendage closure volumes stabilize.
📉 Risk factors
📉Multiple Class II recalls reported in 2026 involving firmware problems in Neuromodulation therapy discs and manufacturing defects in Direxion Torqueable Microcatheters raise potential remediation costs.
🔍Quality control issues associated with recent recalls add operational risk to a portfolio already facing pressure in electrophysiology and WATCHMAN product lines.
Article
Boston Scientific faces renewed investor scrutiny following multiple voluntary Class II device recalls reported in 2026, specifically involving firmware issues in Neuromodulation therapy discs and manufacturing defects in Direxion Torqueable Microcatheters. These quality control incidents introduce operational risks regarding potential remediation costs, tighter regulatory oversight, and possible disruption to the company's interventional and neuromodulation product lines.
The analysis highlights that these recall risks compound existing pressures within the WATCHMAN and electrophysiology franchises. While Simply Wall St notes that recent trial results for the WATCHMAN FLX Pro device show promising noninferiority outcomes, the broader investment case remains contingent on the company's cardiovascular and MedSurg portfolios offsetting weaker performance in specific areas.
Analysts project Boston Scientific to generate US$23.0 billion in revenue and US$4.0 billion in earnings by 2029, with more optimistic estimates reaching US$24.4 billion in revenue and US$4.4 billion in earnings. These long-term forecasts depend heavily on successful product quality maintenance, supply reliability, and the integration of the planned Penumbra acquisition to sustain growth.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Boston Scientific (BSX) shares have experienced a significant decline of approximately 55% over the past 12 months, driven largely by investor concerns regarding weakness in its electrophysiology and WATCHMAN segments. Despite these specific headwinds affecting only about 26% of the company's projected 2025 sales, the broader business has demonstrated underlying resilience.
In the second quarter of 2026, 74% of Boston Scientific's total business grew at a robust rate of 7%, suggesting that the negative sentiment is not reflective of the entire portfolio. This divergence between segment-specific struggles and overall operational growth highlights a potential disconnect in current market valuations.
Management has responded to these challenges by cutting guidance three times, lowering organic growth expectations to a range of 5-6% and trimming EPS guidance to $3.28-$3.32. The author argues that this pessimism may be excessive given the strong performance of the majority of the business, anticipating a return to 5-7% growth and improved 2027 EPS guidance that could trigger a stock repricing.
📉 Stock slumped 55% due to electrophysiology and WATCHMAN weakness.
💰 Challenged segments represent only 26% of projected 2025 sales.
Despite challenges in specific segments, 74% of Boston Scientific's business grew at a robust 7% in Q2 2026, indicating strong underlying operational strength.
The challenged electrophysiology and WATCHMAN segments comprise only 26% of 2025 sales, meaning the majority of the company is not impacted by current weakness.
Risk Factors
Boston Scientific stock has declined substantially over the recent 12-month period, recording a roughly 55% slump driven by investor pessimism.
Management cut guidance three times, lowering organic growth expectations to 5-6% and trimming EPS guidance to $3.28-$3.32 due to weakness in electrophysiology and WATCHMAN.
Boston Scientific (BSX) stock has experienced significant volatility, losing over half its value in the past 12 months compared to the S&P 500's gains. Recent setbacks include a cyberattack in September that likely prevented the company from meeting its guidance, causing shares to drop an additional 8.8% while the broader market rose. The article analyzes how well the medical device maker is equipped to absorb a broader market downturn given its current financial position and historical performance during previous crises.
Management has reported slowing growth, with quarterly revenue growth falling from 20% three quarters earlier to 7.5% in the second quarter of 2026. On its July earnings call, leadership cut the 2026 organic revenue growth outlook to a range of 5% to 6%. The slowdown is attributed to unexpected sharp deceleration in the U.S. market for the WATCHMAN stroke prevention device and rivals capturing more market share in electrophysiology than anticipated.
Despite the slower top-line growth, Boston Scientific maintains strong profitability with an operating margin of 21%, up from 16.6% three years ago. The company's debt stands at 17.8% of its market value, which is below the S&P 500 average of 21%. Historical data shows that during market shocks since 2007, BSX has fallen slightly more than the index on average, with credit and liquidity crises causing the most severe declines.
The article projects potential portfolio impacts if a repeat of the 2008-2009 financial crisis occurs, noting that recovery times can be lengthy. The upcoming January outlook is critical for investors to determine if the growth slowdown is ending or if the business continues to lose speed before any market shock hits.
📉 Stock lost over half its value in past 12 months vs S&P 500 gain.
📊 Quarterly revenue growth slowed from 20% to 7.5% in Q2 2026.
🔍 Management cut 2026 organic revenue outlook to 5%-6% on July earnings call.
Boston Scientific reported second-quarter 2026 revenue of USD 5.44 billion, representing a 7.5 percent increase from the prior year. Adjusted earnings per share reached USD 0.86, marking a 14.7 percent year-over-year rise and exceeding consensus estimates by 3.6 percent. The company demonstrated operating leverage with earnings growth outpacing revenue expansion during this period.
Despite strong quarterly performance, the stock faces a weaker long-term growth outlook for 2026 according to analyst Zacks. While immediate results remain robust, the investment narrative is shifting toward execution over the next product cycle, with new catalysts expected to drive significant results only in 2028. This timeline adjustment places greater emphasis on whether emerging products can offset pressure within established business franchises.
Trading at USD 44.61 per share, Boston Scientific maintains a market capitalization of approximately USD 66.3 billion. The market is currently pricing in slower near-term growth despite the company's ability to deliver faster earnings growth than revenue growth in Q2. Investors are closely monitoring whether reported growth can sustain itself against the reduced annual outlook.
The mixed operating signal for Boston Scientific highlights a key tension between current financial strength and future expectations. While the second-quarter figures show expansion across the business, the longer-term growth path now extends toward 2028. The next critical valuation signal will depend on whether the company can continue to exceed its reduced outlook with reported growth.
📈 Boston Scientific Q2 2026 revenue rose 7.5% to USD 5.44 billion.
💰 Adjusted EPS hit USD 0.86, beating estimates by 3.6%.
Boston Scientific stock traded at approximately USD 43.34 on September 21, 2026, positioning it near the lower end of its 52-week trading range and roughly 18% below its recent high. The company recently reported strong second-quarter fiscal 2026 results, generating revenue of USD 5.44 billion and earnings of USD 907 million, which translated to a profit margin of 16.67%. On a per-share basis, the firm delivered non-GAAP earnings of USD 0.86, beating analyst consensus estimates by roughly 3.6%.
Despite solid operational performance, external analyst sentiment has turned cautious. Oppenheimer lowered its price target from USD 85 to USD 65 while maintaining an Outperform rating, citing a reduction in long-term valuation benchmarks. Concurrently, Zacks assigned a Strong Sell rating based on downward revisions to earnings estimates over the past 60 days and flagged that the stock trades at a forward five-year price-to-sales ratio of 2.85, significantly above the industry average.
The divergence between Boston Scientific's healthy fundamental trajectory and cautious external views creates a complex investment landscape. While the current share price offers potential upside relative to Oppenheimer's reduced target, investors face risks associated with premium valuation multiples and execution concerns highlighted by Zacks. The market is weighing these factors as the company continues to expand profitability against a backdrop of heightened scrutiny on product launches and procedure volumes.
📉 Stock closed at USD 43.34, trading 18% below its 52-week high.
📈 Beat Q2 fiscal 2026 earnings estimates by 3.6% at USD 0.86/share.
💰 Reported Q2 revenue of USD 5.44 billion with margin expansion to 16.67%.
📉 Oppenheimer cut price target to USD 65 while retaining Outperform rating.
⚠️ Zacks assigned Strong Sell due to declining estimates and premium valuation.
📉 Boston Scientific stock closed at USD 43.34, trading roughly 18% below its 52-week high of USD 52.65.
📈 The company beat Q2 fiscal 2026 non-GAAP earnings estimates by 3.6%, delivering USD 0.86 per share versus a consensus of USD 0.83.
💰 Boston Scientific reported Q2 revenue of USD 5.44 billion with a profit margin expansion to 16.67%.
📉 Oppenheimer analyst Suraj Kalia cut the price target from USD 85 to USD 65 while retaining an Outperform rating.
⚠️ Zacks assigned a Strong Sell rating (Rank 5) due to declining earnings estimates and a premium valuation multiple.
📊 The stock trades at a forward five-year P/S ratio of 2.85, approximately 35% above the industry average.
🏥 Boston Scientific operates sterile cleanroom manufacturing for heart catheter systems in Marlborough, MA.
Bullish Signals
Beat Q2 EPS by 3.6% at USD 0.86 vs USD 0.83 consensus.
Profit margin expanded to 16.67%, up from historical low-to-mid teens.
Zacks assigned Strong Sell rating due to downward earnings revisions.
Forward P/S ratio is 35% above industry average at 2.85.
Bullish Signals
Boston Scientific beat Q2 fiscal 2026 non-GAAP earnings expectations by 3.6%, delivering USD 0.86 per share against a consensus of USD 0.83.
The company achieved a profit margin of 16.67% in the second quarter, representing a meaningful expansion from historical low-to-mid teens margins.
Oppenheimer maintains an Outperform rating on Boston Scientific despite lowering its price target, indicating continued belief in long-term upside potential.
Risk Factors
Zacks assigned a Strong Sell rating (Rank 5) citing downward revisions to earnings estimates over the past 60 days.
The stock trades at a forward five-year price-to-sales ratio of 2.85, which is roughly 35% higher than the industry average of 2.11.
Boston Scientific stock closed at USD 43.41 on September 18, 2026, trading significantly below the consensus analyst price target of USD 71.04. The company's shares are currently positioned near their 52-week low of USD 42.20, reflecting market caution regarding competitive pressures and the lingering fallout from a recent cyberattack that has impacted operational assessments.
Analyst sentiment remains divided on the severity of the cyberattack incident. While Citi downgraded the stock citing intensifying competition and the security breach as key risk factors, other analysts maintain Buy ratings, viewing the cyberattack impact as short-lived despite trimming near-term forecasts to account for disruption. This divergence highlights a classic risk-reward debate among investors regarding the company's long-term trajectory versus immediate operational risks.
Valuation metrics suggest Boston Scientific carries a trailing price-earnings ratio of 17.57 with a market capitalization of approximately USD 62.91 billion. Independent valuation models indicate the stock could be trading at a discount to intrinsic value, potentially undervalued by around 56% relative to fair value estimates based on cash flows and historical performance track records.
📉 Shares trade at $43.41, roughly 64% below the $71.04 analyst target.
🛡️ Cyberattack concerns prompted Citi downgrade despite other Buy ratings.
💰 Market cap is $62.91 billion with a trailing P/E of 17.57.
📊 Consensus shows 23 Buys, 6 Holds, and 2 Sells for Moderate Buy.
📈 Independent analysis suggests stock is undervalued by roughly 56%.
📉 Boston Scientific shares closed at USD 43.41 on September 18, 2026, trading roughly 63.6% below the consensus analyst price target of USD 71.04.
🛡️ A recent cyberattack is weighing on analyst sentiment, prompting Citi to downgrade the stock while other houses maintain Buy ratings with trimmed near-term forecasts.
💰 The company holds a market capitalization of approximately USD 62.91 billion and trades at a trailing price-earnings ratio of 17.57.
📊 Analyst consensus consists of 23 Buy, 6 Hold, and 2 Sell recommendations, indicating a Moderate Buy rating overall.
📈 Independent valuation analysis suggests the stock may be undervalued by roughly 56% relative to fair value estimates based on cash flows.
🏥 Boston Scientific operates in the Health Care / Medical Devices sector with shares currently hovering near their 52-week low of USD 42.20.
Bullish Signals
Stock potentially undervalued by ~56% vs fair value.
Citi downgraded due to competition and cyberattack risks.
Analysts trim targets from operational disruption by cyberattack.
Stock near 52-week low of USD 42.20 amid concerns.
Bullish Signals
Independent valuation analysis suggests the stock could be trading at a discount to intrinsic value, potentially undervalued by approximately 56% relative to fair value estimates based on cash flows.
Despite recent headwinds, the sell-side consensus maintains a Moderate Buy rating with an average price target of USD 71.04, implying significant upside potential from current levels.
Risk Factors
Citi downgraded the stock citing intensifying competition in the medical device markets and lingering effects from a recent cyberattack as key risk factors.
Analysts are reassessing near-term forecasts due to operational disruption caused by the cyberattack, leading some to trim their price targets despite maintaining Buy ratings.
The stock is trading near its 52-week low of USD 42.20, reflecting market concerns about the severity of the cyberattack and competitive pressures.
Boston Scientific stock closed at $43.55 on September 17, 2026, near its 52-week low following a downgrade by Citigroup and the lingering effects of an August cyberattack. The medical device manufacturer faces intensified competition in key markets while navigating operational disruptions that have temporarily impaired its ability to process and ship customer orders globally.
Citigroup cut its rating from Buy to Neutral and lowered its price target from $57 to $50, citing ongoing challenges related to the cyber incident and slower growth in core segments. Despite these headwinds, Q2 2026 organic sales grew 7%, hitting the top of the company's guidance range for that period, though full-year 2026 revenue guidance was reduced to a 5% to 6% growth range in late July.
Analyst sentiment remains mixed as other firms maintain bullish stances. TD Cowen reiterated a Buy rating with a $56 price target, while Stifel maintained a Buy with a $60 target, acknowledging disruptions but highlighting the company's efforts to restore operations and its longer-term prospects.
📉 Stock closed at $43.55 near 52-week low after significant year-to-date decline.
🔻 Citigroup downgraded to Neutral with $50 target due to cyberattack fallout.
💻 August cyberattack temporarily impaired order processing before distribution centers normalized.
💰 GuruFocus models stock as 59.8% undervalued with $107.27 fair value estimate.
📉 Boston Scientific stock closed at $43.55 on September 17, 2026, trading near its 52-week low of $42.20 after a significant decline year-to-date.
🔻 Citigroup downgraded the company from Buy to Neutral and lowered its price target from $57 to $50 due to cyberattack fallout and competitive pressures.
💻 An August cyberattack disrupted global operations, temporarily impairing the ability to process orders, though major distribution centers are now operating at normal levels.
📊 Q2 2026 organic sales grew 7%, meeting the top of the guidance range for that specific quarter despite a reduction in full-year revenue guidance.
🔼 TD Cowen maintained a Buy rating with a $56 price target, while Stifel kept a Buy rating with a $60 target, citing operational restoration efforts.
💰 GuruFocus models the stock as approximately 59.8% undervalued with a fair value estimate of $107.27 versus the current trading price.
Bullish Signals
Q2 2026 organic sales grew 7% at guidance top end.
Risk Factors
Citigroup downgraded BSX from Buy to Neutral, lowering target to $50.
August cyberattack disrupts operations and impairs customer order processing.
Intensifying competition in medical devices contributes to operational challenges.
Bullish Signals
Boston Scientific reported Q2 2026 organic sales growth of 7%, which hit the top end of the company's guidance range for that period.
Major distribution centers have returned to operating at or above normal levels following the August cyberattack disruption.
TD Cowen maintains a Buy rating with a $56 price target, indicating confidence in the company's longer-term prospects despite short-term setbacks.
Stifel reiterated a Buy rating with a $60 price target, acknowledging operational disruptions but emphasizing the company's progress in restoring its business.
Risk Factors
Citigroup downgraded Boston Scientific from Buy to Neutral and lowered its price target from $57 to $50 due to ongoing operational challenges.
The August cyberattack has caused lingering operational disruptions, affecting information systems and temporarily impairing the ability to process customer orders.
Intensifying competition in key medical device markets is cited as a factor contributing to the company's current operational challenges and stock weakness.
Boston Scientific (NYSE:BSX) has initiated a voluntary global recall of its LUX-Dx Insertable Cardiac Monitor System and associated software due to delays in atrial fibrillation burden alerts. The US FDA has expressed enforcement interest in this action, highlighting regulatory scrutiny regarding the platform's alert performance.
This recall impacts multiple versions of the hardware and software, directly affecting a core segment of Boston Scientific's portfolio used for patient monitoring. Analysts view this event as a significant risk factor that challenges the company's recent narrative of cleaner execution and successful integration of advanced therapies like FARAPULSE and WATCHMAN.
The primary concern is whether these issues remain contained within the niche cardiac monitoring segment or if they erode physician confidence and hospital purchasing decisions across broader cardiology applications. Investors are now focused on upcoming quarterly filings or FDA communications to determine the quantified impact on procedure volumes and segment revenue.
This recall adds weight to existing regulatory and product lifecycle risks, including earlier device recalls and the discontinuation of the ACURATE valve. The situation tests Boston Scientific's ability to manage operational setbacks arising from continual product refreshes and acquisition integration while maintaining growth and margins in its core business.
📉 Boston Scientific recalls LUX-Dx monitors for delayed AF alerts.
⚖️ FDA enforcement highlights regulatory scrutiny of the cardiac platform.
🏥 Core interventional cardiology portfolio hardware and software affected.
📉 Recall challenges execution narrative for FARAPULSE and WATCHMAN.
⚠️ Risks include eroded physician confidence and hospital purchasing.
📉 Boston Scientific initiates a voluntary global recall of the LUX-Dx Insertable Cardiac Monitor System due to delayed atrial fibrillation burden alerts.
⚖️ The US FDA has taken enforcement interest in the recall, underscoring heightened regulatory scrutiny of the cardiac monitoring platform.
🏥 The affected hardware and software versions impact a core part of Boston Scientific's portfolio used for interventional cardiology procedures.
📉 This event challenges the company's execution narrative regarding advanced therapies like FARAPULSE and WATCHMAN.
⚠️ Analysts are concerned about potential erosion of physician confidence and hospital purchasing decisions across the cardiology segment.
📊 Investors await detailed updates in quarterly filings to assess the quantified impact on procedure volumes and segment revenue.
🔄 The recall exacerbates existing risks related to product lifecycle management, acquisition integration, and operational setbacks.
Risk Factors
Voluntary global recall of LUX-Dx due to software delays.
FDA enforcement scrutiny on cardiac monitoring platform alerts.
Challenges execution narrative for advanced therapies integration.
Risks eroding physician confidence in cardiology segment.
Risk Factors
Boston Scientific initiated a voluntary global recall of its LUX-Dx Insertable Cardiac Monitor System due to software delays in atrial fibrillation burden alerts.
The US FDA has taken enforcement interest in the recall, indicating regulatory scrutiny of the cardiac monitoring platform's alert performance.
This recall impacts multiple versions of the LUX-Dx hardware and software, affecting a core segment of Boston Scientific's portfolio used for patient monitoring.
The event challenges the company's narrative of cleaner execution and successful integration of advanced therapies like FARAPULSE and WATCHMAN.
There is a risk that these issues may erode physician confidence and hospital purchasing decisions across the broader cardiology segment.
The recall adds weight to existing regulatory and product lifecycle risks, including earlier device recalls and the ACURATE valve discontinuation.
Boston Scientific (BSX) shares have seen increased buying activity from US politicians, including Reps. Gilbert Ray Cisneros Jr. and Ro Khanna, who purchased the stock in August 2026 without selling any positions during that period. This follows a broader trend of political interest in the company alongside Accenture.
The stock has declined approximately 50% year-to-date following a significant cyberattack that disrupted manufacturing, order processing, and shipments, leading to the withdrawal of previous earnings guidance. However, bulls argue that major distribution centers have resumed shipping at normal levels and sterilization facilities are operational, suggesting much of the revenue impact may be temporary delays rather than permanent losses.
Despite the cyberattack, the company reported second-quarter revenue growth of 7.5% year-over-year with organic growth of 7%. Key franchises such as Interventional Cardiology, Vascular Therapies, and Neuromodulation delivered double-digit organic growth. Analysts note that BSX trades at a forward P/E of 13.07x, significantly below the healthcare sector median, while maintaining strong margins and substantial cash generation.
Bearish concerns focus on slowing sales for specific products like the WATCHMAN heart implant and potential customer attrition to rivals following the cyberattack. Additionally, the large Penumbra acquisition adds debt that is expected to weigh on earnings in the first year, though bulls maintain that the market may be overreacting to the severity of the situation.
📈 US politicians bought Boston Scientific shares in August 2026 without selling.
📉 Stock down ~50% YTD after cyberattack disrupted manufacturing and shipments.
🏭 Major distribution centers shipping at normal levels by September 8.
💰 Q2 revenue rose 7.5% YoY driven by core franchises like Interventional Cardiology.
📈 US politicians including Reps. Cisneros and Khanna bought Boston Scientific shares in August 2026 without selling any positions during the same period.
📉 The stock is down about 50% year-to-date after a cyberattack disrupted manufacturing and shipments, forcing the company to withdraw its third-quarter and full-year outlook.
🏭 By September 8, Boston Scientific reported that major distribution centers were shipping at or above normal levels and sterilization facilities were operating normally.
💰 Second-quarter revenue rose 7.5% year over year with organic growth of 7%, driven by double-digit gains in core franchises like Interventional Cardiology and Neuromodulation.
📊 The stock trades at a forward non-GAAP P/E of 13.07x, which is approximately 30.64% below the healthcare-sector median of 18.85x.
⚠️ Bears warn that sales growth slowed for the WATCHMAN heart implant and that competitors are taking market share in US heart-rhythm treatment business.
💸 The large Penumbra acquisition adds debt that will weigh on earnings in the first year according to bearish analysis.
🛡️ Bulls argue that hospitals waiting for products and rescheduling procedures suggests disrupted revenue is likely delayed rather than permanently lost.
📉 Sales growth slowed sharply for specific products like WATCHMAN before the cyberattack, indicating underlying business slowdown concerns.
Bullish Signals
Revenue grew 7.5% YoY with 7% organic growth.
Core franchises delivered double-digit organic growth in Q2.
Distribution centers resumed shipping at normal levels by Sept 8.
Penumbra acquisition adds debt weighing on earnings.
Bullish Signals
Boston Scientific reported second-quarter revenue growth of 7.5% year over year with organic growth of 7%, demonstrating continued business expansion.
Core franchises including Interventional Cardiology, Vascular Therapies, and Neuromodulation delivered double-digit organic growth in the second quarter.
Major distribution centers resumed shipping at or above normal levels by September 8, indicating operational recovery from the cyberattack.
Sterilization facilities are operating normally, mitigating concerns about long-term production capacity disruptions.
The stock trades at a forward non-GAAP P/E of 13.07x, significantly below the healthcare-sector median of 18.85x, suggesting potential undervaluation.
The company maintains strong margins and substantial cash generation despite recent operational challenges.
Politicians including Reps. Cisneros and Khanna purchased shares in August 2026 without selling any positions during the same period.
Risk Factors
The company is down about 50% year-to-date following a cyberattack that disrupted manufacturing, order processing, and shipments.
Boston Scientific was forced to withdraw its previous third-quarter and full-year earnings outlook due to the cyberattack impact.
Sales growth slowed sharply for the WATCHMAN heart implant before the cyberattack, indicating underlying business weakness.
Competitors are taking market share in the US heart-rhythm treatment business, posing a competitive risk.
The large Penumbra acquisition adds significant debt that will weigh on earnings in the first year.
Bears argue that the business was already showing signs of slowdown before the cyberattack occurred.
Boston Scientific Corporation (BSX) has been upgraded to a 'Strong Buy' rating, driven by the view that market overreaction has created an attractive entry point for long-term investors. The stock currently trades at a forward P/E ratio of 13.1, which is significantly below its historical average despite demonstrating robust profitability and solid results in the second quarter of 2026.
The company's growth trajectory is being reshaped by specific segment dynamics. While headwinds persist in the WATCHMAN and electrophysiology sectors, these are being effectively offset by strong momentum in Interventional Cardiology and Vascular Therapies. This strategic balance suggests resilience against sector-specific challenges while capitalizing on core business strengths.
Future growth prospects for BSX are supported by the recent Penumbra acquisition and the positioning of its IVL product line, which are expected to drive renewed expansion. These developments are underpinned by a strong balance sheet and favorable trends within the broader medical device sector, reinforcing the company's long-term investment thesis.
📈 Upgraded to 'Strong Buy' as market overreaction creates attractive entry point.
💰 Trades at forward P/E of 13.1, below historical average with solid Q2 results.
🛡️ Growth headwinds offset by strong momentum in Interventional Cardiology and Vascular Therapies.
🚀 Penumbra acquisition and IVL positioning drive renewed growth for the company.
💪 Maintains strong balance sheet supported by favorable medical device sector trends.
📈 Boston Scientific (BSX) is upgraded to 'Strong Buy' as market overreaction creates an attractive entry point for investors.
💰 The stock trades at a forward P/E of 13.1, well below its historical average despite robust profitability and solid Q2 2026 results.
🛡️ Growth headwinds in the WATCHMAN and electrophysiology segments are being offset by strong momentum in Interventional Cardiology and Vascular Therapies.
🚀 The Penumbra acquisition and IVL product positioning are set to drive renewed growth for the company.
💪 BSX maintains a strong balance sheet supported by favorable trends within the medical device sector.
Bullish Signals
Upgraded to 'Strong Buy' as market overreaction creates attractive entry point.
Bullish Signals
Boston Scientific is upgraded to 'Strong Buy' due to market overreaction creating an attractive entry point for long-term investors.
The company trades at a forward P/E of 13.1, which is well below its historical average despite robust profitability and solid Q2 2026 results.
Strong momentum in Interventional Cardiology and Vascular Therapies is offsetting growth headwinds in the WATCHMAN and electrophysiology segments.
The Penumbra acquisition and IVL product positioning are expected to drive renewed growth for the company.
Boston Scientific (NYSE: BSX, ISIN US10117L1017) opened trading on September 14, 2026, following a 0.28% decline to close at USD 42.98 on the NYSE on September 11, 2026. After-hours activity subsequently pushed the share price higher to USD 43.21, suggesting modest stabilization as the stock remained within its established 52-week range and above recent lows. The initial dip was primarily attributed to earlier market pressure linked to a cyberattack that disrupted operations, rather than a broad selloff in the US healthcare sector where major indices posted only fractional moves.
The operational disruption stems from a cyberattack disclosed on August 25, 2026, which temporarily interrupted manufacturing and shipping at the company's sterile cleanroom facility for heart catheter systems located in Marlborough, MA. In response to this incident, Boston Scientific withdrew and reset its financial guidance, a move that had weighed on shares earlier in the week. However, management emphasized that demand and device performance remained intact, with the guidance adjustment reflecting only the near-term impact of the disruption rather than a change in underlying business trends.
As of September 14, 2026, there are no scheduled quarterly earnings releases or annual meetings for Boston Scientific, leaving investor focus centered on the company's recovery trajectory from the cyberattack. Market expectations remain tied to management's comments regarding the pace of manufacturing and logistics recovery following the August 25 incident. While broader macro factors such as updates on healthcare policy or reimbursement rates continue to influence the sector, stock-specific news regarding the resolution of the operational disruption remains the primary driver for Boston Scientific's share performance into the open.
📉 Stock closed at USD 42.98 on Sept 11, 2026, down 0.28%.
🔄 After-hours trading lifted price to USD 43.21 by Sept 14.
⚠️ Cyberattack on Aug 25 disrupted manufacturing and shipping operations.
✅ Management reset guidance due to cyberattack, not business trends.
🔍 Investors focus on recovery pace for logistics and manufacturing.
📉 Boston Scientific stock closed at USD 42.98 on September 11, 2026, marking a 0.28% decline from the prior session.
🔄 After-hours trading lifted the share price to USD 43.21, indicating modest stabilization ahead of the open on September 14, 2026.
⚠️ The recent price dip follows operational disruptions caused by a cyberattack disclosed on August 25, 2026, which temporarily interrupted manufacturing and shipping.
📉 Management withdrew and reset its financial guidance to reflect the near-term impact of the cyberattack rather than changes in underlying business trends.
✅ Company leadership emphasized that demand for products and device performance remain intact despite the operational setbacks.
📊 The stock's trading range on September 11 kept the price within its established 52-week band, staying above the recent low.
🌐 The broader US market backdrop remained relatively soft, framing Boston Scientific's decline as a stock-specific adjustment rather than a sector-wide selloff.
🔍 Investors are currently focused on management's comments regarding the pace of recovery for manufacturing and logistics operations.
📅 No scheduled quarterly earnings release or annual meeting is planned for Boston Scientific during the week of September 14, 2026.
🏥 As a device maker, Boston Scientific's share performance remains sensitive to broader moves in major US indices and healthcare policy updates.
Bullish Signals
After-hours trading lifted price to USD 43.21 on Sept 11, 2026.
Risk Factors
Cyberattack reset financial guidance after disrupting operations.
Manufacturing halted at Marlborough facility due to cyberattack.
Bullish Signals
After-hours trading on September 11, 2026 lifted Boston Scientific's price to USD 43.21, indicating modest stabilization following the prior session's decline.
Management emphasized that demand and device performance remained intact despite the cyberattack, signaling confidence in underlying business trends.
The stock closed comfortably above its recent 52-week low, confirming a contained move rather than a broader selloff.
Risk Factors
Boston Scientific withdrew and reset its financial guidance following a cyberattack that disrupted operations, which weighed on shares earlier in the week.
The company disclosed a cyberattack on August 25, 2026, which temporarily interrupted manufacturing and shipping at its sterile cleanroom facility for heart catheter systems in Marlborough, MA.
Boston Scientific (BSX) shares fell approximately 5.9% on September 9, 2026, after the medical device manufacturer announced that a significant cyberattack would prevent it from meeting its previously issued guidance for the third quarter and full year 2026. The cybersecurity incident, identified on August 25, 2026, disrupted key information technology systems and caused a global interruption of operations, leading the company to withdraw its forecasts for net sales growth and adjusted earnings per share.
Following the news, analyst firm BTIG lowered its price target for Boston Scientific from USD 60.00 to USD 56.00 while maintaining a Buy rating, reflecting increased caution regarding near-term performance. Despite this specific downgrade, the broader analyst consensus remains bullish, with an average 12-month price target of USD 71.46, implying substantial upside potential from the current trading levels around USD 44.98.
Operational recovery efforts are underway, with major distribution centers processing orders at normal levels and manufacturing resuming across most global facilities. The company confirmed that product quality analyses found no impairment to device function or physical integrity, resolving disruptions to remote monitoring activations for certain cardiac devices. Investors await the Q3 2026 earnings update expected in late October for further clarity on the financial impact of the incident.
📉 Cyberattack caused missed Q3 and FY2026 guidance after disrupting global operations.
✅ Internal checks confirm no impairment to device function or physical integrity.
🏭 Manufacturing resumed globally with distribution centers shipping at normal levels.
📉 BTIG cut price target to USD 56 due to operational uncertainty.
📉 Boston Scientific stock dropped roughly 5.9% after the company warned that a cyberattack would cause it to miss Q3 and full-year 2026 guidance for net sales growth and adjusted earnings.
💻 The cybersecurity incident, identified on August 25, 2026, disrupted key IT systems and led to a global interruption of operations affecting the medical device manufacturer.
📉 Analyst firm BTIG cut its price target from USD 60.00 to USD 56.00 while retaining a Buy rating due to the uncertainty surrounding the operational disruption.
🏭 Manufacturing has resumed across most global facilities, and major distribution centers are now processing and shipping orders at or above normal operating levels.
✅ Internal product assessments confirmed no impairment to device function, software code, or physical integrity, ensuring healthcare providers can continue using implants without concern for manufacturing defects.
📈 The consensus 12-month analyst price target remains at USD 71.46, suggesting the stock trades at a significant discount compared to long-term fair value estimates.
📅 Investors expect Boston Scientific to release an updated outlook and Q3 2026 results around October 28, 2026, to clarify the full financial impact of the cyberattack.
Bullish Signals
Manufacturing resumed across most global facilities.
Distribution centers shipping orders at normal levels.
No impairment to device function or integrity.
Remote monitoring disruptions resolved and resuming.
Cyberattack prevents meeting Q3 and FY2026 guidance.
BTIG lowered price target from $60 to $56.
Bullish Signals
Manufacturing operations have resumed across most of the company's global facilities following the cyber incident.
Major distribution centers are currently processing and shipping orders at or above normal operating levels.
Product quality analyses confirmed no impairment to device function, software code, or physical integrity of implants.
Disruptions affecting remote monitoring activations for certain cardiac devices have been resolved and can resume.
Rigorous quality audits verified complete product sterility, allowing healthcare providers to continue using consumables without concern over manufacturing defects.
Risk Factors
The company warned that a cyberattack will prevent it from meeting its previously issued guidance for Q3 and full-year 2026 net sales growth and adjusted earnings per share.
Analyst firm BTIG lowered its price target from USD 60.00 to USD 56.00 in response to the operational disruption caused by the cybersecurity incident.
Boston Scientific (BSX) stock fell 2.3% in premarket trading after the company formally warned it is unlikely to meet its net sales growth and adjusted EPS guidance for both Q3 and full-year 2026. This revised stance follows a cyberattack disclosed on August 25, which has forced management to abandon previous forecasts of 5.5% to 6.5% full-year sales growth and $3.28 to $3.32 adjusted EPS.
The company previously indicated the financial impact of the breach was undetermined, but Tuesday's regulatory filing marked a significant deterioration in outlook. Wall Street analysts had expected full-year adjusted EPS of $3.30 on net sales of $21.35 billion, while Q3 consensus estimates were set at 81 cents EPS and $5.26 billion in sales.
Despite the negative guidance update, Boston Scientific stated it has not found evidence of ongoing unauthorized access and expects to recover some lost revenue as operations ramp back up. The company plans to provide a full update on its operational and financial outlook, including the specific impact of the cyberattack, during its Q3 earnings call scheduled for October 28.
📉 BSX stock dropped 2.3% after warning it will miss Q3 and full-year earnings guidance due to a cyberattack.
💰 Company now expects to miss previously guided full-year sales growth of 5.5%-6.5% and adjusted EPS of $3.28-$3.32.
📉 Stock has fallen 50% year-to-date and trades near its 52-week low amid analyst downgrades citing cyber concerns.
🔒 Investigation remains active with no evidence of ongoing unauthorized access despite normal distribution center operations.
📅 BSX will provide a comprehensive operational and financial outlook update during its Q3 earnings call on October 28.
📉 Boston Scientific stock dropped 2.3% to $46.68 after formally warning it will likely miss Q3 and full-year 2026 earnings and sales guidance due to a cyberattack.
🚫 The company shifted from previously stating the financial impact was undetermined to explicitly saying it is 'unlikely to meet' its net sales growth and adjusted EPS targets.
💰 Previous guidance included full-year sales growth of 5.5% to 6.5% and adjusted EPS between $3.28 and $3.32, which are now expected to be missed.
📊 Wall Street consensus for full-year adjusted EPS was $3.30 on net sales of $21.35 billion, with Q3 EPS expectations at 81 cents.
📉 The stock has underperformed significantly, falling 50% year-to-date and 55% over the past 12 months while trading near its 52-week low.
🔍 Analysts Argus Research, Baird, JPMorgan, and Bank of America have downgraded or trimmed price targets citing growth concerns and cyberattack impacts.
🏭 Major distribution centers were processing and shipping products at normal levels as of September 5, though this did not offset the guidance miss.
🔒 Boston Scientific reported no evidence of ongoing unauthorized access but confirmed the investigation remains active.
📅 The company will provide a comprehensive update on operational and financial outlooks regarding the cyberattack during its Q3 earnings call on October 28.
🏥 Medtech peers Abbott and Medtronic have also faced cybersecurity incidents in 2026, adding broader sector pressure to Boston Scientific's situation.
Bullish Signals
No evidence found of ongoing unauthorized access to systems.
Risk Factors
Warned unlikely to meet Q3/2026 sales/EPS guidance due to cyberattack.
Bullish Signals
Boston Scientific stated it has not found evidence of ongoing unauthorized access to its systems following the cyberattack.
The company expects to recover some portion of lost revenue as operations ramp back up, customer orders are fulfilled, and backlogs are reduced.
Major distribution centers were processing and shipping products at or above normal levels as of September 5.
Risk Factors
Boston Scientific formally warned it is unlikely to meet its net sales growth and adjusted EPS guidance for Q3 and full-year 2026 due to a cyberattack.
The company's stance hardened from previously stating the financial impact was undetermined to explicitly forecasting a miss on earnings and sales targets.
Analysts Argus Research, Baird, JPMorgan, and Bank of America have downgraded or trimmed price targets citing growth concerns and cyberattack impacts.
The stock has fallen 50% year-to-date and 55% over the past 12 months, trading far below its 52-week high of $109.50.
Medtech peers Abbott and Medtronic have also dealt with cybersecurity incidents in 2026, keeping broader sector sentiment under pressure.
On July 21, 2026, Boston Scientific Corporation announced a major global restructuring initiative approved by its Board of Directors, aimed at improving cost efficiency and advancing strategic growth objectives. The company estimates total pre-tax charges between $700 million and $800 million for the program, which is scheduled to commence in 2026 and be substantially completed by the end of 2029.
The restructuring plan focuses heavily on supply chain optimization and manufacturing realignment, with transfer costs estimated between $300 million and $350 million representing the largest portion of expenses. This involves relocating production lines across global facilities to enhance operational efficiency, reduce redundancies, and align capacity with market demand while maintaining regulatory compliance.
Workforce adjustments are also part of the initiative, with termination benefits estimated between $275 million and $300 million. Despite these reductions, Boston Scientific plans to create new positions in growth sectors. The company anticipates generating approximately $500 million in annual pre-tax expense savings once fully implemented, with a significant portion of these savings intended for reinvestment in strategic growth initiatives.
The multi-year timeline allows the medical device manufacturer to manage manufacturing transfers and organizational changes with minimal disruption. Management views this restructuring as a strategic move to reallocate resources toward priority growth areas and strengthen its competitive position within the healthcare technology industry, rather than merely cutting costs.
📅 Boston Scientific announces global restructuring with $700M-$800M pre-tax charges starting 2026.
🏭 Manufacturing realignment involves $300M-$350M transfer costs to optimize supply chain efficiency.
👥 Workforce reductions include $275M-$300M termination benefits alongside new growth sector hiring.
💰 Program targets $500M annual pre-tax savings by 2029 for reinvestment in growth.
⏳ Restructuring completes by end of 2029 with additional $125M-$150M in program expenses.
📅 Boston Scientific announced a global restructuring plan on July 21, 2026, with pre-tax charges estimated between $700 million and $800 million.
🏭 The initiative prioritizes supply chain optimization and manufacturing realignment, involving transfer costs of $300 million to $350 million.
👥 Workforce reductions are expected alongside new job creation in growth sectors, with termination benefits estimated at $275 million to $300 million.
💰 The program is projected to deliver approximately $500 million in annual pre-tax expense savings once fully implemented by 2029.
🔄 Manufacturing lines will be transferred among global facilities to enhance operational efficiency and reduce redundancies.
📈 A significant portion of the realized savings is planned to be reinvested in strategic growth initiatives for future revenue expansion.
⏳ The restructuring activities are set to commence in 2026 and be substantially completed by the end of 2029.
🛡️ Additional expenses include consulting fees, contractual cancellations, program management, and accelerated depreciation totaling $125 million to $150 million.
Bullish Signals
Restructuring delivers $500M annual pre-tax savings by 2029.
Reinvesting savings into strategic growth initiatives strengthens positioning.
Risk Factors
Pre-tax charges range from $700M to $800M.
Termination benefits estimated between $275M and $300M.
Bullish Signals
The restructuring plan is designed to deliver approximately $500 million in annual pre-tax expense savings once fully implemented by 2029.
Management intends to reinvest a significant portion of the realized savings into strategic growth initiatives to strengthen competitive positioning.
Risk Factors
The company will incur total pre-tax charges between $700 million and $800 million, with $600 million to $700 million expected as future cash outflows.
Workforce reductions are anticipated as part of the restructuring, requiring termination benefits estimated between $275 million and $300 million.
Medical device manufacturer Boston Scientific (BSX) disclosed on Wednesday that it is currently suffering from an active cyberattack that is significantly disrupting its operations. The company stated in an SEC filing that the incident has compromised access to critical information systems and applications, specifically hindering its ability to process and ship products. Management emphasized that while they are working diligently to restore affected functions, a specific timeline for full restoration remains unknown.
Shares of Boston Scientific fell sharply following the disclosure, dropping 4.5% in morning trading on Wednesday. The stock decline adds to existing pressure on the $72 billion market-cap company, which has already seen its shares nearly halve this year due to a weak profit forecast issued earlier in the first quarter. Analysts at Piper Sandler noted that the inability to ship orders will likely adversely impact sales growth for a business already facing slowing momentum.
Matt O'Brien of Piper Sandler, who spoke with company management, estimated that BSX may be able to resume shipping all products in less than three weeks. However, the uncertainty surrounding the duration of the disruption and the potential for extended downtime poses a significant risk to revenue generation. The cyberattack represents a material operational event occurring at a time when the company is already navigating challenges related to sales growth deceleration.
Analysts warn that the combination of the ongoing cyber incident and previously weak guidance creates a difficult environment for the stock. The disruption affects core logistics and order processing capabilities, directly threatening short-term revenue realization. Investors are now focused on the speed of recovery and whether the operational halt will result in missed quarterly targets given the current sales slowdown.
🚨 Cyberattack disrupts Boston Scientific operations and information systems access.
📉 Shares fell 4.5% as breach impacts product shipments and sales.
⏳ Full shipping operations expected to resume in less than three weeks.
Boston Scientific (BSX) shares have declined significantly in 2026, dropping over 52% from their September 2025 peak to close at $51.83 on August 14, 2026. Despite this price action, the company's fundamental financial performance remains robust, with Q2 net sales rising 7.5% to $5.442bn and gross margins expanding 305 basis points to 70.7%. Operating income surged 43.8% to $1.178bn, and adjusted EPS of $0.86 beat the company's own guidance range, indicating that the stock decline is driven by a multiple compression rather than a deterioration in earnings power.
The core issue driving the valuation re-rating is a divergence in growth rates between domestic and international markets. While US revenue for flagship franchises like Watchman and electrophysiology has slowed to low single digits or flat growth, these same segments are growing at over 20% internationally. Analysts interpret this geographic split as evidence of market saturation and increased competition within the United States, specifically in pulsed-field ablation and left-atrial-appendage closure, rather than a decline in overall demand for the company's therapies.
A major strategic development complicating the outlook is Boston Scientific's agreement to acquire Penumbra for approximately $14.5bn, announced in January 2026. This deal, structured with roughly 73% cash and 27% stock, has already impacted the balance sheet, reducing cash reserves and increasing debt obligations. The acquisition aims to re-enter the neurovascular market but introduces sequencing risks as the company funds a massive purchase while its highest-multiple US franchises stabilize in a mature, lower-growth phase.
The investment thesis hinges on whether the US growth lines can stabilize in the mid-single digits or if they will decelerate further. Bulls argue that at current levels, trading at roughly 15.7 times adjusted EPS guidance, the stock is undervalued relative to its high-margin profile and pending acquisition synergies. Bears warn that if US growth falters into negative territory while international expansion slows, the multiple could contract further, potentially pushing the share price toward $40.
📉 Stock down 52.1% from peak due to growth multiple re-rating.
💰 Q2 sales rose 7.5% with margins expanding 305 bps.
🌍 International growth exceeded 20% while US revenue stalled.
💸 Acquiring Penumbra for $14.5bn reduces cash and increases debt.
📉 BSX stock closed at $51.83 on August 14, 2026, down 52.1% from its September 2025 peak, reflecting a market re-rating of growth multiples rather than earnings deterioration.
💰 Q2 net sales rose 7.5% to $5.442bn with gross margins expanding 305 basis points to 70.7%, while operating income jumped 43.8% to $1.178bn.
🌍 International growth for Watchman and electrophysiology franchises exceeded 20%, masking a near-stall in US domestic revenue which grew only 2.9% and 3.2% respectively.
💸 The company agreed to acquire Penumbra for approximately $14.5bn, reducing cash equivalents from $1.965bn to $539m while increasing current debt obligations to $1.709bn.
📊 Adjusted EPS of $0.86 beat the guidance range of $0.82–$0.84, though management noted the beat was partially aided by favorable tax results.
🏥 US Watchman revenue is projected to be roughly flat sequentially following a 2.9% year-over-year increase in the June quarter.
📈 Analyst consensus price target stands at $62.69 with 26 out of 29 analysts maintaining a buy rating despite reduced targets.
🔬 Pulsed-field ablation and left-atrial-appendage closure devices face US market saturation, limiting new account acquisition opportunities for the incumbent leader.
📉 Full-year organic revenue growth is guided at 5–6%, with third-quarter guidance set between 3–5% as the company transitions to a mature growth phase.
⚖️ Diluted share count fell by approximately 1.3% year-over-year to 1,474.8m as the company retires stock while assembling cash for the Penumbra acquisition.
Bullish Signals
Q2 adjusted EPS of $0.86 beat the company's own guidance range of $0.82–$0.84, demonstrating strong execution despite market headwinds.
Gross margins expanded significantly by 305 basis points to reach 70.7%, indicating strong pricing power and operational efficiency.
Operating income surged 43.8% to $1.178bn, reflecting robust underlying profitability even as revenue growth moderates.
International markets are driving double-digit growth for key franchises like Watchman (20%) and electrophysiology (23%), providing a stable revenue base.
The company is retiring shares, reducing the diluted count by 1.3% while accumulating cash to fund its strategic Penumbra acquisition.
Analyst consensus remains overwhelmingly positive with 26 out of 29 analysts rating the stock as a buy, signaling confidence in long-term value.
Risk Factors
US revenue for flagship franchises Watchman and electrophysiology has stalled, growing only 2.9% and 3.2% respectively compared to over 20% international growth.
The stock price has fallen 52.1% from its peak as the market re-prices expectations from high-growth multiples to a mature 15.7x earnings multiple.
Management signaled that Watchman revenue would be roughly flat sequentially, triggering a significant sell-off in May 2026.
The massive $14.5bn acquisition of Penumbra has strained the balance sheet, reducing cash reserves and increasing debt obligations significantly.
US markets for pulsed-field ablation and left-atrial-appendage closure are facing saturation, limiting future organic growth potential in the company's highest-margin segments.
Analyst Tom Werner maintains a buy rating on Boston Scientific (BSX) with a $66 price target, suggesting significant upside potential if negative earnings revisions stabilize. The article highlights that the company has reset market expectations by slashing guidance and openly acknowledging competitive pressures within its WATCHMAN and electrophysiology segments.
Valuation metrics appear attractive at 13.7x forward earnings, though further stock appreciation is contingent on management halting guidance cuts and demonstrating consistent execution. The analyst expects achievable 2024 EPS near the high end of the previous guidance range at $3.32.
Looking ahead to 2025, there is potential for EPS growth between $3.69 and $4.00 if operational improvements materialize as planned. While recent results were not terrible, clear signs of deterioration are noted in specific business units, requiring management to address these challenges to unlock the full value implied by the current valuation.
📈 Analyst Tom Werner maintains a buy rating with a $66 price target.
📉 Company slashed guidance due to competitive pressures in key segments.
💰 Current valuation is attractive at 13.7x forward earnings.
🎯 Expected 2024 EPS reaches high end of guidance at $3.32.
⚠️ Further upside depends on halting guidance cuts and consistent execution.
📈 Analyst Tom Werner retains a buy rating on Boston Scientific (BSX) with a $66 price target.
📉 The company has slashed guidance and acknowledged competitive pressures in WATCHMAN and electrophysiology segments.
💰 Current valuation is assessed as attractive at 13.7x forward earnings.
🎯 Analyst expects achievable 2024 EPS at the high end of guidance, specifically $3.32.
🚀 Potential for 2025 EPS growth ranges from $3.69 to $4.00 if operational improvements materialize.
⚠️ Further upside is contingent on management halting guidance cuts and delivering execution consistency.
📊 Recent results were not terrible but show clear signs of deterioration in specific segments.
Bullish Signals
Analyst buy rating with $66 price target.
Attractive valuation at 13.7x forward earnings.
2024 EPS expected at high end of $3.32 guidance.
Potential 2025 EPS growth between $3.69 and $4.00.
Risk Factors
Company cut earnings guidance signaling market expectation reset.
Competitive pressures challenge WATCHMAN and electrophysiology segments.
Specific business units show clear signs of deterioration.
Stock upside depends on halting guidance cuts trajectory.
Bullish Signals
Analyst maintains a buy rating with a $66 price target, implying substantial upside if negative revisions stabilize.
Valuation is currently attractive at 13.7x forward earnings, providing a margin of safety for investors.
2024 EPS is expected to be achievable at the high end of guidance ($3.32), indicating operational resilience.
There is potential for significant 2025 EPS growth between $3.69 and $4.00 if management executes operational improvements.
Risk Factors
The company has recently cut its earnings guidance, signaling a reset of expectations by the market.
Competitive pressures are explicitly identified as a challenge in the WATCHMAN and electrophysiology segments.
Clear signs of deterioration are present within specific business units despite recent results not being terrible.
Future stock upside is contingent on management successfully halting guidance cuts, indicating current trajectory risks.
Aristotle Atlantic Partners LLC increased its stake in Boston Scientific Corporation (NYSE: BSX) by 5.9% during the first quarter, purchasing an additional 12,480 shares to hold a total position of 223,520 shares valued at $14.026 million. Other institutional investors also adjusted their positions, with FWL Investment Management LLC, Swiss RE Ltd., and Garton & Associates Financial Advisors LLC each establishing new stakes valued around $26,000, while Bangor Savings Bank significantly increased its holdings by 94.7%.
Analyst sentiment remains mixed but generally positive regarding the medical device manufacturer's long-term prospects. Recent reports from major firms include Robert W. Baird setting a $70 target price and Leerink Partners lowering its target to $74 while maintaining an 'outperform' rating. Conversely, Stifel Nicolaus reduced its target to $65 with a 'buy' rating, and Truist Financial lowered its objective to $62, though it retained a 'buy' stance. The consensus price target stands at $79.84 based on data from MarketBeat.com.
The company recently authorized a substantial stock repurchase plan of $5 billion, signaling management's confidence in the stock's valuation and commitment to returning capital to shareholders. This authorization allows for the purchase of up to 6.4% of outstanding shares through open market transactions. Additionally, insider activity has been bullish, with directors Edward J. Ludwig and David C. Habiger acquiring significant shares totaling over $328,000 in May, bringing total insider ownership to 0.34%.
📈 Aristotle Atlantic Partners increased stake by 5.9% to hold $14.026 million.
💰 Board authorized $5 billion stock repurchase program covering up to 6.4% of shares.
📊 Analysts rate stock 'Moderate Buy' with price target of $79.84.
👔 Insiders purchased over $328,000 in shares during May.
🏥 Company focuses on less-invasive procedures for cardiovascular and other conditions.
📈 Aristotle Atlantic Partners LLC boosted its Boston Scientific position by 5.9% in Q1, adding 12,480 shares for a total holding of 223,520 shares valued at $14.026 million.
🏦 Several other institutions initiated new positions or increased stakes, including Bangor Savings Bank which grew its holdings by 94.7% to own 292 shares.
💰 Boston Scientific's Board authorized a $5 billion stock repurchase program, permitting the purchase of up to 6.4% of outstanding shares via open market buys.
📊 Analyst consensus rating is 'Moderate Buy' with a collective price target of $79.84, though individual targets vary from $62 to $87.
👔 Insider buying activity was strong in May, with directors Ludwig and Habiger purchasing shares worth over $328,000 combined.
📉 The stock trades at a PEG ratio of 0.85 and a market capitalization of $65.78 billion as of the latest reporting period.
🏥 Boston Scientific focuses on less-invasive medical procedures for cardiovascular, digestive, urologic, pulmonary, and chronic pain conditions.
Bullish Signals
$5B buyback authorization signals undervaluation.
Insiders bought $328K in May.
Major firms maintain Buy/Outperform ratings.
Low PEG ratio of 0.85.
Risk Factors
Analysts lowered targets: Stifel $75 to $65, Truist $64 to $62.
Stock trades below 50-day ($47.21) and 200-day ($64.06) moving averages.
Bullish Signals
The company has secured a $5 billion authorization for stock buybacks, indicating management believes the shares are undervalued.
Insiders have been net buyers recently, with directors acquiring over $328,000 worth of stock in May alone.
Analysts maintain 'Buy' or 'Outperform' ratings from major firms like Leerink Partners and Truist Financial despite some target price reductions.
The stock possesses a low PEG ratio of 0.85, suggesting the company's growth rate is priced at a reasonable multiple relative to earnings.
Risk Factors
Some analysts have lowered their price targets recently, with Stifel Nicolaus cutting its target from $75 to $65 and Truist Financial reducing its objective from $64 to $62.
The stock is currently trading below its 50-day moving average of $47.21 and significantly below its 200-day moving average of $64.06.
Assetmark Inc. increased its stake in Boston Scientific Corporation (NYSE: BSX) by 36.9% during the first quarter, purchasing an additional 39,270 shares to hold a total of 145,679 shares valued at $9.14 million. Several other institutional investors also adjusted their positions, including new stakes from FWL Investment Management, Swiss RE Ltd., and Garton & Associates, each valued around $26,000, while Bangor Savings Bank grew its holding by 94.7% to own 292 shares worth $28,000.
The article details Boston Scientific's financial metrics as of the reporting period, noting a market capitalization of $65.20 billion, a price-to-earnings ratio of 18.35, and a beta of 0.58. The stock traded with a 52-week range between $42.20 and $109.50, opening at $43.86 on the reported Tuesday. Key liquidity ratios include a quick ratio of 1.22 and a current ratio of 1.90, alongside a debt-to-equity ratio of 0.42.
Corporate developments highlighted include a board-approved share repurchase program authorizing $5.00 billion in buybacks, representing up to 6.4% of outstanding shares, signaling management's view that the stock is undervalued. Insider trading activity saw directors David C. Habiger and Cheryl Pegus purchase shares totaling over $225,000, while analysts provided mixed ratings with a consensus 'Moderate Buy' and an average target price of $79.84.
📈 Assetmark Inc. increased stake to 145,679 shares worth $9.14 million.
🏦 Hedge funds and institutions own 89.07% of outstanding stock.
💰 Board authorized new $5.00 billion share repurchase program.
📉 Analysts show mixed sentiment with one downgrade to peer perform.
👔 Insiders bought 9,800 shares valued at $554,012 recently.
📈 Assetmark Inc. raised its stake in Boston Scientific by 36.9% to own 145,679 shares valued at $9.14 million.
🏦 Hedge funds and institutional investors collectively hold 89.07% of the company's outstanding stock.
💰 The company announced a new $5.00 billion share repurchase program authorized by its board.
📉 Analysts show mixed sentiment with Wolfe Research downgrading to 'peer perform' while others maintain 'buy' ratings.
📊 Boston Scientific trades at a P/E ratio of 18.35 with a market cap of $65.20 billion.
👔 Insiders acquired 9,800 shares valued at $554,012 over the last three months.
📉 The stock has a beta of 0.58 and a PEG ratio of 0.84 indicating potential growth efficiency.
🏥 The medical device firm focuses on less-invasive procedures for cardiovascular and other conditions.
Bullish Signals
Company announced $5B share repurchase program.
Assetmark increased position by 36.9%.
Bangor Savings Bank grew stake 94.7%.
Quick ratio of 1.22 and current ratio 1.90.
Insiders bought 9,800 shares worth $554k.
Risk Factors
Downgraded to peer perform by Wolfe Research on May 29th.
Price target lowered from $75.00 to $65.00 by Stifel Nicolaus.
Trading below 50-day average of $47.99 and 200-day average of $65.29.
Bullish Signals
The company announced a $5.00 billion share repurchase program, authorizing the buyback of up to 6.4% of outstanding shares, which typically signals management confidence in undervalued stock.
Assetmark Inc. significantly increased its position by 36.9%, adding 39,270 shares to its holdings, indicating strong institutional interest.
Bangor Savings Bank grew its stake by 94.7% in the fourth quarter, demonstrating growing confidence from smaller institutional investors.
The company maintains a healthy balance sheet with a quick ratio of 1.22 and a current ratio of 1.90.
Insiders have been net buyers recently, acquiring 9,800 shares valued at $554,012 in the last three months.
Risk Factors
Wolfe Research downgraded Boston Scientific from an 'outperform' rating to a 'peer perform' rating on May 29th.
Stifel Nicolaus lowered its price target from $75.00 to $65.00, though it maintained a 'buy' rating.
The stock is currently trading below its 50-day moving average of $47.99 and significantly below its 200-day moving average of $65.29.
Boston Scientific Corporation (NYSE: BSX) saw increased institutional interest in the first quarter of 2026, with AIA Group Ltd growing its holdings by 18.2% to own 186,665 shares valued at $11.7 million. Several other institutions, including FWL Investment Management and Bangor Savings Bank, also established or increased their positions during the quarter, while hedge funds and institutional investors collectively hold 89.07% of the company's stock.
Analyst sentiment remains mixed but generally positive regarding the company's valuation and future prospects. Major firms like Evercore, Mizuho, Jefferies, Bank of America, and BTIG have issued buy or outperform ratings with target prices ranging from $65 to $100. The consensus rating is a 'Moderate Buy' with an average price target of $79.84, though recent downgrades from higher targets suggest some caution among analysts.
Financially, Boston Scientific reported strong performance in the quarter ended April 22nd, beating earnings estimates with $0.80 EPS and revenue of $5.20 billion, an 11.6% year-over-year increase. The company has set guidance for Q2 2026 EPS between $0.82 and $0.84 and full-year 2026 EPS between $3.34 and $3.41. Additionally, the board authorized a new $5 billion share repurchase program, signaling confidence in the stock's undervaluation.
The company maintains a robust balance sheet with a market cap of $65.33 billion, a PEG ratio of 0.84, and healthy liquidity ratios. Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific focuses on less-invasive medical procedures for cardiovascular, digestive, urologic, pulmonary, and chronic pain conditions. Recent insider activity includes directors purchasing shares worth over $225,000 combined, further supporting the bullish outlook.
📈 AIA Group stake rose 18.2% to 186,665 shares worth $11.7 million.
🏦 Institutional investors FWL and Bangor increased positions in Q2 and Q4.
📊 Q1 earnings beat estimates at $0.80 EPS on $5.20 billion revenue.
💰 Board authorized $5 billion share repurchase program covering 6.4% of shares.
📉 Analysts Mizuho, Jefferies, and BofA lowered price targets but kept buy ratings.
📈 AIA Group Ltd increased its stake in Boston Scientific by 18.2% to 186,665 shares valued at $11.7 million during the first quarter.
🏦 Multiple institutional investors including FWL Investment Management and Bangor Savings Bank established or significantly increased their positions in Q2 and Q4.
📊 The company reported Q1 earnings of $0.80 EPS, beating analyst estimates of $0.79 on revenue of $5.20 billion.
🚀 Revenue grew 11.6% year-over-year to $5.20 billion, demonstrating strong top-line growth in the medical device sector.
💰 The board authorized a new $5 billion share repurchase program, allowing the purchase of up to 6.4% of outstanding shares.
🎯 Analyst consensus rating is 'Moderate Buy' with an average price target of $79.84, though some firms lowered targets recently.
📉 Mizuho cut its price target from $90 to $70 while maintaining an 'outperform' rating on the stock.
📉 Jefferies and Bank of America also lowered their price targets to $67 and $68 respectively, though both maintain buy ratings.
💼 Insiders purchased 9,800 shares valued at $554,012 in the last quarter, with directors Habiger and Pegus buying directly.
📈 The stock trades at a PEG ratio of 0.84 and a market cap of $65.33 billion with a beta of 0.58.
Bullish Signals
Beat Q1 estimates with $0.80 EPS vs $0.79 consensus.
Bancreek Capital Management LP increased its stake in Boston Scientific Corporation (NYSE: BSX) by purchasing 39,000 shares worth approximately $2.45 million during the first quarter, making the stock its sixth-largest holding at 10.6%. Several other institutional investors also adjusted their positions, with Frazier Financial Advisors boosting holdings by 56.3%, SouthState Bank increasing them by 4.0%, and Mill Capital Management raising its stake by 39.6% in the same period.
Analyst sentiment regarding Boston Scientific remains mixed but generally positive, with an average rating of 'Moderate Buy' and a consensus price target of $79.84. Recent analyst actions include Daiwa Securities downgrading the stock to a 'hold', Raymond James lowering its price target to $88.00, and Leerink Partners reducing its objective to $74.00, while Piper Sandler maintained an 'overweight' rating with a $65.00 target.
Financially, Boston Scientific reported strong quarterly results with revenue of $5.20 billion, beating estimates by $10 million, and earnings per share of $0.80 versus the consensus of $0.79. The company has set guidance for Q2 2026 EPS between $0.82 and $0.84 and full-year 2026 EPS between $3.34 and $3.41, with revenue growing 11.6% year-over-year.
The company announced a new $5.00 billion stock repurchase authorization, signaling management's confidence in the stock's value. Insider activity was also notable, with Director Edward J. Ludwig purchasing 3,580 shares and Director Cheryl Pegus buying 1,770 shares, totaling over $980,000 in insider acquisitions within the last 90 days.
📈 Bancreek Capital acquired 39,000 shares for $2.45 million in Q1.
💰 Revenue hit $5.20 billion, beating estimates by $10 million.
🚀 Company authorized a new $5.0 billion stock repurchase program.
📊 Q2 EPS guidance set between $0.82 and $0.84 per share.
📉 Daiwa Securities downgraded stock from 'strong-buy' to 'hold'.
📈 Bancreek Capital Management LP acquired 39,000 shares of Boston Scientific for approximately $2.45 million in Q1.
🏦 Multiple institutional investors including Frazier Financial Advisors and Mill Capital Management increased their stakes significantly.
💰 The company reported revenue of $5.20 billion, surpassing analyst estimates by $10 million.
📊 Earnings per share reached $0.80, beating the consensus estimate of $0.79 for the quarter.
🚀 Boston Scientific authorized a new $5.00 billion stock repurchase program.
🎯 Q2 2026 EPS guidance is set between $0.82 and $0.84 per share.
📉 Analyst price targets vary, with Raymond James at $88.00 and Leerink Partners at $74.00.
👔 Director Edward J. Ludwig purchased 3,580 shares worth approximately $203,000 in a single transaction.
📉 Daiwa Securities Group downgraded the stock from 'strong-buy' to 'hold' recently.
📈 Revenue grew 11.6% compared to the same quarter last year.
Bullish Signals
Revenue hit $5.20 billion, beating estimates by $10 million.
Earnings per share reached $0.80, surpassing the $0.79 consensus.
Management authorized a new $5.00 billion stock repurchase plan.
Revenue grew 11.6% year-over-year to $5.20 billion this quarter.
Insiders bought over $980,000 of stock in the last 90 days.
Risk Factors
Daiwa downgraded Boston Scientific to hold.
Raymond Financial cut price target to $88.
Leerink Partners lowered objective to $74.
Wall Street Zen downgraded stock to hold.
Bullish Signals
Boston Scientific reported revenue of $5.20 billion, exceeding analyst consensus estimates by $10 million.
The company achieved earnings per share of $0.80, beating the expected $0.79 consensus.
Management authorized a new $5.00 billion stock repurchase plan, indicating confidence in undervaluation.
Revenue grew 11.6% year-over-year to $5.20 billion during the reported quarter.
Insiders have acquired over $980,000 worth of company stock in the last 90 days.
The firm maintains a strong balance sheet with a quick ratio of 1.22 and current ratio of 1.90.
Risk Factors
Daiwa Securities Group downgraded Boston Scientific from 'strong-buy' to 'hold' rating.
Raymond Financial lowered its price target from $97.00 to $88.00 on the stock.
Leerink Partners decreased its price objective from $87.00 to $74.00 despite maintaining an 'outperform' rating.
Wall Street Zen downgraded the stock from 'buy' to 'hold' in a recent report.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)